BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12477049)

  • 21. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
    [No Abstract]   [Full Text] [Related]  

  • 22. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR; in relation to enzyme activity.
    Sigmond J; Loves WJ; Kroep JR; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1347-50. PubMed ID: 15571256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Boven E; Stegmann AP; Hermsen M; Vermorken JB; Pinedo HM; Peters GJ
    Cancer Res; 1994 Aug; 54(15):4138-43. PubMed ID: 8033147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
    Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
    Hodzic J; Giovannetti E; Diosdado B; Adema AD; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1214-22. PubMed ID: 22132977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
    Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
    Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
    Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.
    van der Wilt CL; Kroep JR; Loves WJ; Rots MG; Van Groeningen CJ; Kaspers GJ; Peters GJ
    Eur J Cancer; 2003 Mar; 39(5):691-7. PubMed ID: 12628850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM; Gagnon J; Primeau M; Momparler RL
    Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
    Attia F; Fathy S; Anani M; Hassan A; Attia F; Ibrahim G; Elazab M
    J Clin Lab Anal; 2020 Nov; 34(11):e23457. PubMed ID: 32671914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
    Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
    Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.
    Galmarini CM; Clarke ML; Jordheim L; Santos CL; Cros E; Mackey JR; Dumontet C
    BMC Pharmacol; 2004 May; 4():8. PubMed ID: 15157282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
    Ashida R; Nakata B; Shigekawa M; Mizuno N; Sawaki A; Hirakawa K; Arakawa T; Yamao K
    J Exp Clin Cancer Res; 2009 Jun; 28(1):83. PubMed ID: 19531250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas.
    Szatmári T; Huszty G; Désaknai S; Spasokoukotskaja T; Sasvári-Székely M; Staub M; Esik O; Sáfrány G; Lumniczky K
    Cancer Gene Ther; 2008 Mar; 15(3):154-64. PubMed ID: 18188186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.